ClinicalTrials.gg
RecruitingNCT04570423Updated Oct 28, 2026

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

A Phase 2 interventional study of Eflapegrastim and Chemotherapy in Solid Tumors and Lymphoma, sponsored by Spectrum Pharmaceuticals, Inc. Recruiting at 5 sites in United States. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
1 Month to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,910 studies in Lymphoma with a site in United States — 161 open to participants now, 288 under way, 15 of them phase 3. Lymphoma · United States.

Planned enrollment
725th of 1,595
40 · median 36
Started
2021
with 52 others
Phase 2
668 of 1,910
36 open now
Primary completion
2027-10
later than 172 of 281 live
Registered
1,664th of 1,910
by date

Among the 1,910 studies in Lymphoma with a site in United States, this one is the 725th largest by planned enrollment of the 1,595 interventional ones that give a count, is one of 53 that started in 2021, is one of 668 in phase 2, reaches primary completion later than 172 of the 281 other live ones, and was the 1,664th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

161 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 1 Month to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,910 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.

Read the detailed description

This is a Phase 2, open label, multicenter study of eflapegrastim in pediatric participants (≥1 month to \<17 years) with solid tumors or lymphoma.

Approximately 40 participants will be enrolled and assigned to one of 4 age-based cohorts. Participants enrolled in Cohort 1 will be followed for dose-limiting toxicities (DLTs) prior to initiating parallel enrollment into Cohorts 2 through 4.

All participants will receive chemotherapy as Standard of Care after which a subcutaneous (SC) dose of eflapegrastim will be administered up to 4 treatment cycles.

03

Conditions studied

  • Solid Tumors
  • Lymphoma

Browse trials for

Keywords

  • Lymphomas
  • Solid Tumors
  • Chemotherapy
04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must have a pathologic/histologic confirmed newly diagnosed//recurrent solid tumor or lymphoma without bone marrow involvement.
  2. Participant must be a candidate to receive myelosuppressive chemotherapy, with a febrile neutropenia rate of at least 20% as outlined in the National Comprehensive Cancer Network (NCCN) guidelines.
  3. Participant has adequate hematological, renal, and hepatic function.
  4. Participant must have an echocardiogram (ECHO) or multigated acquisition () within 14 days of Screening if receiving a cardiotoxic therapy and have a cardiac ejection fraction of >50%.
  5. Participant must have a lumbar puncture, if clinically indicated, to rule out central nervous system (CNS) involvement within 14 days of study entry.
  6. Participant has a performance level ≥50% for patients ≥16 years of age or a Lansky performance level ≥50 for children \<16 years of age.

Exclusion criteria

Exclusion Criteria:

  1. Participant has an uncontrollable infection, has an underlying medical condition, and/or another serious illness that would impair the ability of the participant to receive protocol-specified treatment.
  2. Participant has had previous exposure to filgrastim (within 7 days), pegfilgrastim (within 14 days), or other granulocyte colony stimulating factor (G-CSF) products in clinical development within 2 weeks prior to the administration of study drug (eflapegrastim)
  3. Participant requires concurrent radiation therapy specifically in Cycle 1.
  4. Participant has had prior bone marrow or hematopoietic stem cell transplant and/or has concurrent bone marrow involvement in their , including leukemia.
  5. Participant has had spinal radiation therapy within 30 days prior to study enrollment.
  6. Participant has used any drugs, biologics or devices within 30 days prior to study treatment or plans to use any of these during the study.
  7. Participant has a known sensitivity or previous reactions to any of the G-CSF products.
  8. Participant with active CNS disease.
  9. Participant has not recovered from previous treatment adverse events to ≤Grade 1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1: ≥12 to <17 years

    Participants will receive a SC injection of eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).

    Drug: Eflapegrastim · Drug: Chemotherapy

  • Experimental
    Cohort 2: ≥6 to <12 years

    Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).

    Drug: Eflapegrastim · Drug: Chemotherapy

  • Experimental
    Cohort 3: ≥2 to <6 years

    Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).

    Drug: Eflapegrastim · Drug: Chemotherapy

  • Experimental
    Cohort 4: ≥1 month to <2 years

    Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).

    Drug: Eflapegrastim · Drug: Chemotherapy

Interventions

  • Eflapegrastim supplied in prefilled, single-use syringes for SC injection.

    Also known as: Rolontis®, SPI-2012

  • DrugChemotherapy

    Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE is any AE that occurs from the first dose of the study drug until 35 days after the last dose of study drug, or on the day a new/additional chemotherapy regimen, or on the day another granulocyte-colony stimulating factor (G-CSF) is administered.

    Time frame: From first dose of study drug to 35 days after the last dose of the study drug (Up to approximately 16 months)

Secondary outcomes

  1. Percentage of Participants With Severe Neutropenia in Cycle 1

    Severe neutropenia is defined as absolute neutrophil count (ANC) less than 0.5\*10\^9/liter (L).

    Time frame: Cycle 1 (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy selected)

  2. Time to Absolute Neutrophil Count (ANC) Recovery of Severe Neutropenia in Cycle 1

    Time to ANC recovery of severe neutropenia is defined as the time from chemotherapy administration until the participants ANC increases to ≥1.0\*10\^9/L after the expected nadir.

    Time frame: Cycle 1 (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy selected)

  3. Number of Participants With Febrile Neutropenia in Cycle 1

    Febrile neutropenia is defined as ANC less than 0.5\*10\^9/L with a single temperature of \>38.3 degree Celsius (°C) or a sustained temperature of ≥38°C for more than 1 hour.

    Time frame: Cycle 1 (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy selected)

  4. Peak Concentration (Cmax) of Eflapegrastim in Cycle 1

    Time frame: Pre-dose and at multiple time points (up to Day 9 [Cohorts 1-3] and Day 6 [Cohort 4]) post-dose in Cycle 1 (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy selected)

  5. Time to Reach Peak Concentration (Tmax) of Eflapegrastim in Cycle 1

    Time frame: Pre-dose and at multiple time points (up to Day 9 [Cohorts 1-3] and Day 6 [Cohort 4]) post-dose in Cycle 1 (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy selected)

  6. Elimination Half-life (t½) of Eflapegrastim in Cycle 1

    Time frame: Pre-dose and at multiple time points (up to Day 9 [Cohorts 1-3] and Day 6 [Cohort 4]) post-dose in Cycle 1 (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy selected)

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Oct 2027, 77 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 77 months is above that.

Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2020
First posted
Sep 30, 2020
StartActual
May 20, 2021
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04570423
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
May 20, 2021
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Howard Franklin, MD
Contact
Hfranklin@assertiotx.com
224.419.7106

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eflapegrastim

Start the discussion